Dual κ-agonist/μ-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease

Annals of Neurology

Volumn 77, Issue 6, 2015, Pages 930-941

  Potts, Lisa F ^a,e   Park, Eun S ^b   Woo, Jong Min ^b,f   Dyavar Shetty, Bhagya L ^a   Singh, Arun ^a   Braithwaite, Steven P ^c   Voronkov, Michael ^c   Papa, Stella M ^a,d   Mouradian, M Maral ^b,c  

^a EMORY UNIVERSITY   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c MentiNova   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

^f Korea Institute of Oriental Medicine (KIOM)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 5; DYNORPHIN A; KAPPA OPIATE RECEPTOR; LEVODOPA; MU OPIATE RECEPTOR; NALBUPHINE; PHOSPHOPROTEIN DARPP 32; PRODYNORPHIN; SODIUM CHLORIDE; TRANSCRIPTION FACTOR FOSB; ANTIPARKINSON AGENT; NARCOTIC ANALGESIC AGENT;

ADULT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSTONIA; FEMALE; HAPLORHINI; LEVODOPA-INDUCED DYSKINESIA; MALE; MOTOR DYSFUNCTION; NONHUMAN; OROFACIAL DYSKINESIA; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; DYSKINESIA, DRUG-INDUCED; MACACA; NEOSTRIATUM;

ANALGESICS, OPIOID; ANIMALS; ANTIPARKINSON AGENTS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; FEMALE; LEVODOPA; MACACA; MALE; NALBUPHINE; NEOSTRIATUM; PARKINSON DISEASE; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU;

EID: 84930038059     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24375     Document Type: Article

References (59)

1. Manson A, Stirpe P, Schrag A,. Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life. J Parkinsons Dis 2012; 2: 189-198.
2. Verhagen Metman L, Del Dotto P, van den Munckhof P, et al., Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998; 50: 1323-1326.
3. Snow BJ, Macdonald L, McAuley D, Wallis W,. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 2000; 23: 82-85.
4. Sawada H, Oeda T, Kuno S, et al., Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial. PLoS One 2010; 5: e15298.
5. Brotchie JM,. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord 2005; 20: 919-931.
6. Jenner P,. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 2008; 9: 665-677.
7. Hanrieder J, Ljungdahl A, Falth M, et al., L-DOPA-induced dyskinesia is associated with regional increase of striatal dynorphin peptides as elucidated by imaging mass spectrometry. Mol Cell Proteomics 2011; 10: M111.009308.
8. Huot P, Johnston TH, Koprich JB, et al., The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease. Pharmacol Rev 2013; 65: 171-222.
9. Herrero MT, Augood SJ, Hirsch EC, et al., Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum. Neuroscience 1995; 68: 1189-1198.
10. Nisbet AP, Foster OJ, Kingsbury A, et al., Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience 1995; 66: 361-376.
11. Calon F, Birdi S, Rajput AH, et al., Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J Neuropathol Exp Neurol 2002; 61: 186-196.
12. Henry B, Duty S, Fox SH, et al., Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. Exp Neurol 2003; 183: 458-468.
13. Bishop C, Krolewski DM, Eskow KL, et al., Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats. J Neurosci Res 2009; 87: 1645-1658.
14. Tamim MK, Samadi P, Morissette M, et al., Effect of non-dopaminergic drug treatment on levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides. Neuropharmacology 2010; 58: 286-296.
15. Bourdenx M, Nilsson A, Wadensten H, et al., Abnormal structure-specific peptide transmission and processing in a primate model of Parkinson's disease and l-DOPA-induced dyskinesia. Neurobiol Dis 2014; 62: 307-312.
16. Piccini P, Weeks RA, Brooks DJ,. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann Neurol 1997; 42: 720-726.
17. Aubert I, Guigoni C, Li Q, et al., Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia. Biol Psychiatry 2007; 61: 836-844.
18. Johansson PA, Andersson M, Andersson KE, Cenci MA,. Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia. Neurobiol Dis 2001; 8: 220-239.
19. Mansour A, Fox CA, Burke S, et al., Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: an in situ hybridization study. J Comp Neurol 1994; 350: 412-438.
20. Samadi P, Gregoire L, Bedard PJ,. Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems. Neuropharmacology 2003; 45: 954-963.
21. Fox S, Silverdale M, Kellett M, et al., Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease. Mov Disord 2004; 19: 554-560.
22. Klintenberg R, Svenningsson P, Gunne L, Andren PE,. Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism. J Neural Transm 2002; 109: 1295-1307.
23. Rascol O, Fabre N, Blin O, et al., Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Mov Disord 1994; 9: 437-440.
24. Henry B, Fox SH, Crossman AR, Brotchie JM,. Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Exp Neurol 2001; 171: 139-146.
25. Koprich JB, Fox SH, Johnston TH, et al., The selective mu-opioid receptor antagonist ADl5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease. Mov Disord 2011; 26: 1225-1233.
26. Marin C, Bove J, Bonastre M, Tolosa E,. Effect of acute and chronic administration of U50,488, a kappa opioid receptor agonist, in 6-OHDA-lesioned rats chronically treated with levodopa. Exp Neurol 2003; 183: 66-73.
27. Cox H, Togasaki DM, Chen L, et al., The selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates. Exp Neurol 2007; 205: 101-107.
28. Ikeda K, Yoshikawa S, Kurokawa T, et al., TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease. Eur J Pharmacol 2009; 620: 42-48.
29. Berg D, Becker G, Reiners K,. Reduction of dyskinesia and induction of akinesia induced by morphine in two parkinsonian patients with severe sciatica. J Neural Transm 1999; 106: 725-728.
30. Samadi P, Gregoire L, Bedard PJ,. The opioid agonist morphine decreases the dyskinetic response to dopaminergic agents in parkinsonian monkeys. Neurobiol Dis 2004; 16: 246-253.
31. De Souza EB, Schmidt WK, Kuhar MJ,. Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic. J Pharmacol Exp Ther 1988; 244: 391-402.
32. Cao X, Liang L, Hadcock JR, et al., Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys. J Pharmacol Exp Ther 2007; 323: 318-326.
33. Papa SM, Chase TN,. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol 1996; 39: 574-578.
34. Uthayathas S, Shaffer CL, Menniti FS, Schmidt CJ, Papa SM,. Assessment of adverse effects of neurotropic drugs in monkeys with the "Drug Effects on the Nervous System" (DENS) scale. J. Neurosci Methods 2013; 215: 97-102.
35. Wikberg T,. Simultaneous determination of levodopa, its main metabolites and carbidopa in plasma by liquid chromatography. J Pharm Biomed Anal 1991; 9: 167-176.
36. Saxer C, Niina M, Nakashima A, et al., Simultaneous determination of levodopa and 3-O-methyldopa in human plasma by liquid chromatography with electrochemical detection. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 802: 299-305.
37. Andersson M, Hilbertson A, Cenci MA,. Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol Dis 1999; 6: 461-474.
38. Cao X, Yasuda T, Uthayathas S, et al., Striatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movements. J Neurosci 2010; 30: 7335-7343.
39. Engber TM, Susel Z, Kuo S, et al., Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res 1991; 552: 113-118.
40. Greengard P, Allen PB, Nairn AC,. Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 1999; 23: 435-447.
41. Aubert I, Guigoni C, Hakansson K, et al., Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 2005; 57: 17-26.
42. Kuan WL, Lin R, Tyers P, Barker RA,. The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventral mesencephalon transplants and levodopa-induced dyskinesias. Neurobiol Dis 2007; 25: 594-608.
43. Santini E, Sgambato-Faure V, Li Q, et al., Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia. PLoS One 2010; 5: e12322.
44. Tekumalla PK, Calon F, Rahman Z, et al., Elevated levels of DeltaFosB and RGS9 in striatum in Parkinson's disease. Biol Psychiatry 2001; 50: 813-816.
45. Fasano S, Bezard E, D'Antoni A, et al., Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia. Proc Natl Acad Sci U S A 2010; 107: 21824-21829.
46. Lindgren HS, Rylander D, Iderberg H, et al., Putaminal upregulation of FosB/DeltaFosB-like immunoreactivity in Parkinson's disease patients with dyskinesia. J Parkinsons Dis 2011; 1: 347-357.
47. Picconi B, Centonze D, Hakansson K, et al., Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 2003; 6: 501-506.
48. Feyder M, Bonito-Oliva A, Fisone G,. L-DOPA-induced dyskinesia and abnormal signaling in striatal medium spiny neurons: focus on dopamine d1 receptor-mediated transmission. Front Behav Neurosci 2011; 5: 71.
49. Gerfen CR, Engber TM, Mahan LC, et al., D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990; 250: 1429-1432.
50. Santini E, Valjent E, Usiello A, et al., Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci 2007; 27: 6995-7005.
51. Bateup HS, Santini E, Shen W, et al., Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors. Proc Natl Acad Sci U S A 2010; 107: 14845-14850.
52. Mouradian MM, Heuser IJ, Baronti F, et al., Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol 1989; 25: 523-526.
53. Bateup HS, Svenningsson P, Kuroiwa M, et al., Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat Neurosci 2008; 11: 932-939.
54. Kuroiwa M, Bateup HS, Shuto T, et al., Regulation of DARPP-32 phosphorylation by three distinct dopamine D1-like receptor signaling pathways in the neostriatum. J Neurochem 2008; 107: 1014-1026.
55. Chagniel L, Robitaille C, Lebel M, Cyr M,. Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model. Neurobiol Dis 2012; 45: 645-655.
56. Bibb JA, Snyder GL, Nishi A, et al., Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature 1999; 402: 669-671.
57. Chergui K, Svenningsson P, Greengard P,. Cyclin-dependent kinase 5 regulates dopaminergic and glutamatergic transmission in the striatum. Proc Natl Acad Sci U S A 2004; 101: 2191-2196.
58. Chen J, Zhang Y, Kelz MB, et al., Induction of cyclin-dependent kinase 5 in the hippocampus by chronic electroconvulsive seizures: role of [Delta]FosB. J Neurosci 2000; 20: 8965-8971.
59. Westin JE, Vercammen L, Strome EM, et al., Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiatry 2007; 62: 800-810.